Daisuke Sugiyama

9PUBLICATIONS
100CO-AUTHORS
Haematological tumoursMolecular targetsMedical infection agents (incl. prions)Tumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 15, 2026
Local, but not circulating, complement C3 shapes immune checkpoint blockade efficacy by controlling myeloid cell infiltration.

|Apr 15, 2026
On-demand GLUT3 expression augments CAR T cell metabolic fitness and antitumor efficacy in preclinical models of glioblastoma.

|Dec 10, 2025
Microglia Display Heterogeneous Initial Responses to Disseminated Tumor Cells.

Takahiro Tsuji, Haruka Hirose, Daisuke Sugiyama

|Feb 12, 2025
Coactivation of innate immune suppressive cells induces acquired resistance against combined TLR agonism and PD-1 blockade.

Hitomi Nishinakamura, Sayoko Shinya, Takuma Irie

|Nov 27, 2024
The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment.

Ayaka Tsuge, Sho Watanabe, Akihito Kawazoe

|Dec 02, 2022
Significance of regulatory T cells in cancer immunology and immunotherapy.

Daisuke Sugiyama, Kunihiko Hinohara, Hiroyoshi Nishikawa

Pageof 2

Frequent Collaborators

8 joint publications

Hiroyoshi Nishikawa

3 joint publications

Atsushi Enomoto

3 joint publications

Shohei Koyama

2 joint publications

Keisuke Watanabe